Medline Inc. IPO - What You Need to Know

Thinking about buying into the Medline IPO? It is a massive name in the medical world. Before you invest your hard-earned money, let’s break down the business in plain English.

1. What does this company actually do?

Think of Medline as the "Amazon of hospitals." If a healthcare facility needs it—from surgical gowns and gloves to complex diagnostic tools—Medline supplies it. They operate in two main lanes:

• Medline Brand: They make and sell over 350,000 of their own medical products.
• Supply Chain Solutions: They distribute products from over 1,300 other brands and help hospitals manage their warehouses.

They have a huge physical footprint, including 26 million square feet of warehouse space and a fleet of 2,100 trucks. By using AI and robotics, they offer next-day delivery to 95% of their U.S. customers. This makes them an essential utility for the healthcare system.

2. How do they make money?

Medline uses a "Prime Vendor" model. Hospitals sign long-term contracts to buy most of their supplies from Medline. This creates a "flywheel" effect: by handling a hospital's entire supply chain, Medline lowers the hospital's costs, which builds trust and encourages the hospital to buy more of Medline’s own branded products.

Why this matters: Medline’s own products are much more profitable than the third-party goods they distribute. They have a massive opportunity to grow; they estimate that if they convince existing customers to switch to Medline’s own products, it could generate an extra $1.3 billion in profit.

3. Is the business healthy?

Medline is a growth machine. They have grown their sales every year since they started. In 2025, they generated $28.4 billion in sales. The business model is very "sticky"—once a hospital signs a contract, they rarely leave. Medline has kept over 98% of its customers over the last five years. This stability provides predictable income, even when the economy is shaky.

4. What’s the deal with this IPO?

Medline trades on the Nasdaq under the ticker “MDLN.”

It is important to know who is behind the curtain. The founding Mills family remains involved, but the company is heavily influenced by private equity firms—Blackstone, Carlyle, and Hellman & Friedman.

A Note on Structure: Medline uses a complex setup called an "UP-C" structure. The company is split into two parts for tax purposes, which allows early owners to keep certain tax benefits. Because of this, Medline signed a "tax receivable agreement" where they promised to pay 90% of certain tax savings to those early owners. As of March 2026, Medline had a debt of over $4 billion for these future payments. This is a large obligation that will use up cash that could otherwise go toward paying off debt, research, or dividends.

5. What are the main risks?

• The "Sponsor" Factor: Private equity firms own a controlling interest. They may prioritize short-term financial moves to help them sell their shares later, rather than focusing on long-term growth.
• Tax Obligations: The tax agreement creates a multi-billion dollar debt to early owners. These payments are mandatory and could limit the company's cash for years.
• Pricing Pressure: Hospitals operate on thin budgets and constantly pressure suppliers like Medline to lower prices.
• Competition: Medline faces intense competition from giants like Cardinal Health and McKesson. These companies also have large networks and compete for the same hospital contracts.

Final Thoughts for Investors

IPOs can be a wild ride. The price often jumps around on the first day, so don't feel pressured to buy the second it hits the market.

Your next steps:

1. Read the Prospectus: Before you invest, look for the official S-1 filing on the SEC’s EDGAR website. It contains the fine print on their debt and legal risks.
2. Watch the "Lock-up" Period: Keep an eye on when private equity firms are allowed to sell their shares. A large sell-off by these insiders can sometimes cause the stock price to drop.
3. Check the Competition: Compare Medline’s growth and profit margins against its public rivals, Cardinal Health and McKesson, to see if the valuation makes sense.

Disclaimer: I am an AI, not a financial advisor. Investing in IPOs carries significant risk. Always do your own research or talk to a professional before making investment decisions.